Positron Emission Tomography Scanning in Cancer

References

• Positron Emission Tomography and Autoradiography. Principles and Applications for the Brain and Heart, M E Phelps, J C Mazziotta, H R Schelbert. Raven Press, New York 1986
   Google Scholar
• Hawkins R A, Phelps M E. Applications of PET in clinical oncology. Cancer Metast Rev 1988; 7: 119–142
   PubMed Web of Science ®Google Scholar
• Beaney R P. Positron emission tomography in the study of human tumors. Semin Nucl Med 1984; 14(4)324–341
   PubMed Web of Science ®Google Scholar
• Ott R J. The applications of positron emission tomography to oncology. Br J Cancer 1991; 63(3)343–345, (editorial)
   PubMed Web of Science ®Google Scholar
• Strauss L G, Conti P S. The applications of PET in clinical oncology. J Nucl Med 1991; 32: 623–648
   PubMed Web of Science ®Google Scholar
• Hawkins R A, Hoh C, Dahlbom M, Choi Y, Glaspy J, Tse N, Slamon D, Chen B, Mess C, Maddahi J, Phelps M E. PET cancer evaluations with FDG. J Nucl Med 1991; 32: 1555–1558
   PubMed Web of Science ®Google Scholar
• Sokoloff L, Reivich M, Kennedy C, Des Rosiers M H, Patlak C S, Pettigrew K D, Sakurada O, Shinohara M. The (14C)-deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28: 897–916
   PubMed Web of Science ®Google Scholar
• Phelps M E, Huang S-C, Hoffman E J, Selin C, Sokoloff L, Kuhl D E. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)-2-fluoro-2-deoxy-D-glucose: Validation of method. Ann Neurol 1979; 6: 371–388
   PubMed Web of Science ®Google Scholar
• Reivich M, Kuhl D E, Wolf A, Greenberg J, Phelps M E, Ido T, Casella V, Fowler J, Hoffman E, Alavi A, Som P, Sokoloff L. The (18F)-fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979; 44: 127–137
   PubMed Web of Science ®Google Scholar
• Huang S C, Phelps M E, Hoffman E J, Sideris K, Selin C J, Kuhl D E. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 1980; 238: E69–E82
   PubMed Web of Science ®Google Scholar
• Hawkins R A, Phelps M E, Huang S C. Effects of temporal sampling, glucose metabolic rates and disruptions of the blood brain barrier (BBB) on the FDG model with and without a vascular compartment: Studies in human brain tumors with PET. J Cereb Blood Flow Metab 1986; 6: 170–183
   PubMed Web of Science ®Google Scholar
• Di Chiro G, Paz R L, De La Brooks R A, Sokoloff L, Kornblith P L, Smith B H, Patronas N J, Kufta C V, Kessler R M, Johnston G S, Manning R G, Wolf A P. Glucose utilization of cerebral gliomas measured by [18F]fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323–1329
   PubMed Web of Science ®Google Scholar
• Di Chiro G. Positron emission tomography using [18F]fluorode-oxyglucose in brain tumors. Invest Radiol 1987; 22: 360–371
   PubMed Web of Science ®Google Scholar
• Di Chiro G, Oldfield E, Wright D C, De Michele D, Katz D A, Patronas N J, Doppman J L, Larson S M, Ito M, Kufta C V. Cerebral necrosis after radiotherapy and/or intra-arterial chemotherapy for brain tumors: PE and neuropathologic studies. Am J Roentgenol 1988; 150: 189–197
   PubMed Web of Science ®Google Scholar
• Patronas N J, Di Chiro D G, Kufta C, Bairamian D, Kornblith P L, Simon R, Larson S M. Prediction of survival in glioma patients by PET. J Neurosurg 1986; 62: 816–822
   Web of Science ®Google Scholar
• Di Chiro G, Brooks R A. PET-FDG of untreated and treated cerebral gliomas. J Nucl Med 1988; 29: 421–422
   PubMed Web of Science ®Google Scholar
• Gallagher B M, Fowler J S, Gutterson N I, MacGregor R R, Wan C N, Wolf A P. Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of [18F]2-deoxyglucose. J Nucl Med 1989; 19: 1154–1161
   Google Scholar
• Warburg O. The Metabolism of Tumors. Constabel, London 1930
   Google Scholar
• Warburg O. On the origin of cancer cells. Science 1956; 123: 309–314
   PubMed Web of Science ®Google Scholar
• Flier J S, Mueckler M M, Usher P, Lodish H F. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235: 1492–1495
   PubMed Web of Science ®Google Scholar
• Hiraki Y, McMorrow I M, Birnbaum M J. The regulation of glucose transporter gene expression by cyclic adenosine monophosphate in NIH3T3 fibroblasts. Endocrinol 1989; 3: 1470–1476
   Web of Science ®Google Scholar
• Hiraki Y, Rosen O M, Birnbaum M J. Growth factors rapidly induce expression of the glucose transporter gene. J Biol Chem 1988; 27: 263
   Google Scholar
• Slater D W, Baldwin S A, Lienhard G E, Weber M J. Proteins antigenically related to the human erythrocyte glucose transporter in normal and Rous sarcoma virus-transformed chicken embryo fibroblasts. Proc Natl Acad Sci USA 1982; 79: 1540–1544
   PubMed Web of Science ®Google Scholar
• Birnbaum M J, Haspel H C, Rosen O M. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science 1987; 235: 1495–1498
   PubMed Web of Science ®Google Scholar
• Weber G. Enzymology of cancer cells. N Engl J Med 1977; 296: 486–493; 541–551
   PubMed Web of Science ®Google Scholar
• Som P, Atkins H L, Bandoypadhyay D, Fowler J S, MacGregor R R, Matsui K, Oster Z H, Sacker D F, Shiue C Y, Turner H, Wan C-N, Wolf A P, Zabinski S V. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (18F): Nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21: 670–675
   PubMed Web of Science ®Google Scholar
• Hawkins R A, Choi Y, Huang S C, Messa C, Hoh C K, Phelps M E. Quantitating tumor glucose metabolism with FDG and PET. J Nucl Med 1992; 33: 339–344
   PubMed Web of Science ®Google Scholar
• Schelstraete K, Simons M, Deman J, Vermeulen L, Slegers G, Vandecasteele C, Goethals P, De Schryver A. Uptake of 13N-ammonia by human tumors as studies by positron emission tomography. Br J Radiol 1982; 55: 797–804
   PubMed Web of Science ®Google Scholar
• Ito M, Lammertsma A A, Wise R JS, Bernardi S, Frackowiak R SJ, Heather J D, McKenzie C G, Thomas D GT, Jones T. Measurement of regional cerebral blood flow and oxygen utilization in patients with cerebral blood flow and oxygen utilization in patients with cerebral tumors using 15O and positron emission tomography: Analytical techniques and preliminary results. Neuroradiology 1982; 23: 63–74
   PubMed Web of Science ®Google Scholar
• Rhodes C G, Wise R JS, Gibbs J M, Frackowiak R SJ, Hatazawa J, Palmer A J, Thomas D GT, Jones T. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 1983; 14: 614–626
   PubMed Web of Science ®Google Scholar
• Beaney R P, Lammertsma A A, Jones T, McKenzie C G, Halnan K E. Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilization, and blood volume in patients with breast carcinoma. Lancet 1984; I(8369)131–134
   Google Scholar
• Kubota K, Matsuzawa, Fujiwara T, Abe Y, Ito M, Hatazawa J, Ido T, Ishiwata K, Watanuki S. Differential diagnosis of solitary pulmonary nodules with positron emission tomography using [IIC]L- Methionine. J Comput Assist Tomogr 1988; 12(5)794–796
   PubMed Web of Science ®Google Scholar
• Kubota K, Matsuzawa T, Takahashi T, Fujiwara T, Kinomura S, Ido T, Sato T, Kubota R, Tada M, Ishiwata K. Rapid and sensitive response of carbon-II-L-methionine tumor uptake to irradiation. J Nucl Med 1989; 30: 2012–2016
   PubMed Web of Science ®Google Scholar
• Kiichi I, Vaalburg W, Elsinga P H, Paans A MJ, Woldring M G. Comparison of L-[I-IIC]methionine and L-methyl-[IIC]methionine for measuring in vivo protein synthesis rates with PET. J Nucl Med 1988; 29: 1419–1427
   PubMed Web of Science ®Google Scholar
• Mosskin M, Von Holst H, Bergstrom M, Collins V P, Eriksson L, Johnstrom P, Noren G. Positron emission tomography with IIC-methionine and computed tomography of intracranial tumours compared with histopathologic examination of multiple biopsies. Acta Radiol 1987; 28: 673–681
   PubMed Web of Science ®Google Scholar
• Keen R E, Barrio J R, Huang S C, Hawkins R A, Phelps M E. In-vivo protein synthesis rates with leucyl-transfer RNA used as precursor pool: Determination of biochemical parameters to structure tracer kinetic models for positron emission tomography. J Cereb Blood Flow Metab 1989; 9: 429–445
   PubMed Web of Science ®Google Scholar
• Hawkins R A, Huang S C, Barrio J R, Keen R E, Feng D, Mazziotta J C, Phelps M E. Estimation of local cerebral protein synthesis rates with L-[I-IIC]leucine and PET: Methods, model and results in animals and humans. J Cereb Blood Flow Metab 1989; 9: 446–460
   PubMed Web of Science ®Google Scholar
• Gelbard A S, Benua R S, Laughlin J S, Rosen B, Reiman R E, McDonald J M. Quantitative scanning of osteogenic sarcoma with nitrogen-13-labeled L-glutamate. J Nucl Med 1979; 20: 782–784
   PubMed Web of Science ®Google Scholar
• Knapp W H, Helus F, Layer K, Panzer M. Nitrogen-13-glutamate uptake and perfusion in Walker 256 carcinosarcoma before and after single-dose-irradiation. J Nucl Med 1986; 27: 1604–1610
   PubMed Web of Science ®Google Scholar
• Reiman R E, Rosen G, Gelbard A S, Benua R S, Laughlin J S. Imaging of primary Ewing sarcoma with N-13 L-glutamate. Radiology 1982; 142: 494–500
   Google Scholar
• Shields A F, Lim K, Grierson J, Link J, Krohn K A. Utilization of labeled thymidine in DNA synthesis: studies for PET. J Nucl Med 1990; 31: 337–342
   PubMed Web of Science ®Google Scholar
• Mariat P, Ferrant A, Labar D, Cogneau M, Bol A, Michel C, Michaux J L, Sokal G. In vivo measurement of carbon-II-thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med 1988; 29: 1633–1637
   PubMed Web of Science ®Google Scholar
• Poupeye E, Counsell R E, De Leenheer A, Slegers G, Goethals P. Synthesis of IIC-labelled thymidine for tumor visualization using positron emission tomography. Int J Radiat Appl Instrument. Part A. Appl Radiat Isotopes 1989; 40: 57–61
   Web of Science ®Google Scholar
• Ishiwata K, Ido T, Yoshinao A, Matsuzawa T, Murakami M. Studies on 18F-labeled pyrimidines. III. Biochemical investigation of 18F-labeled pyrimidines and comparison with 3H-deoxythymidine in tumor-bearing rats and mice. Eur J Nucl Med 1985; 10: 39–44
   PubMedGoogle Scholar
• Hiesiger E, Follwer J S, Wolf A P, Logan J, Brodie J D, McPherson D, MacGregor R R, Christman D R, Volkow N D, Flamm E. Serial PET studies of human cerebral malignancy with [I-IIC]putrescine and [I-IIC]2-deoxy-D-glucose. J Nucl Med 1987; 28: 1251–1261
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Kubota K, Sato T, Matsuzawa T, Tada M, Iwata R, Itoh M, Hatazawa J, Sato K, Fukuda H, Ido T. N-[18F]fluoracetyl-D-glucosamine: A potential agent for cancer diagnosis. J Nucl Med 1990; 31: 1654–1658
   PubMed Web of Science ®Google Scholar
• Yen C K, Budinger T F, Friedland R P, Derenzo S E, Huesman R H, O'Brien H A. Brain tumor evaluation using Rb-82 and positron emission tomography. J Nucl Med 1982; 23: 532–537
   PubMed Web of Science ®Google Scholar
• Lammertsma A A, Brooks D J, Frackowiak R SJ, Heather J D, Jones T. A method to quantitate the fractional extraction of rubidium-82 across the blood barrier using positron emission tomography. J Cereb Blood Flow Metab 1984; 4: 523–534
   PubMed Web of Science ®Google Scholar
• Brooks D J, Kensett M J, Lammertsma A A, Leenders K L, Horlock P L, Kensett M J, Marshall J, Thomas D J, Jones T. Quantitative measurement of blood brain barrier permeability using rubidium-82 and positron emission tomography. J Cereb Blood Flow Metab 1984; 4: 535–545
   PubMed Web of Science ®Google Scholar
• Jarden J O, Dhawan V, Poltorak A, Posner J B, Rottenberg D A. Positron emission tomographic measurement of blood-to-brain and blood-to-tumor transport of 82Rb: The effect of dexamethasone and whole-brain radiation therapy. Ann Neurol 1985; 18: 636–646
   PubMed Web of Science ®Google Scholar
• Hawkins R A, Phelps M E, Huang S C, Wapenski J A, Grimm P D, Parker R G, Juillard G, Greenberg P. A kinetic evaluation of blood brain barrier permeability in human brain tumors with 68Ga EDTA and positron computed tomography. J Cereb Blood Flow Metab 1984; 4: 504–515
   Google Scholar
• Kessler R M, Goble J C, Bird J H, Birton M E, Doppman J L, Rapoport S I, Barranger J A. Measurement of blood-brain barrier permeability with positron emission tomography and [68Ga]EDTA. J Cereb Blood Flow Metab 1984; 4: 323–328
   PubMed Web of Science ®Google Scholar
• Katzenellenbogen J A, Carlson K E, Heiman D F, Goswami R. Receptor-binding radiopharmaceuticals for imaging breast tumors: Estrogen-receptor interactions and selectivity of tissue up-take of halogenated estrogen analogs. J Nucl Med 1980; 21: 550–558
   PubMed Web of Science ®Google Scholar
• Mintun M A, Welch M J, Siegel B A, Mathias C J, Brodack J W, McGuire A H, Katzenellenbogen J A. Breast cancer: PET imaging of estrogen receptors. Radiology 1988; 169: 45–48
   PubMed Web of Science ®Google Scholar
• Wilson C B, Snook D E, Dhokia B, Taylor C V, Watson I A, Lammertsma A A, Lambrecht R, Waxman J, Jones T, Epenetos A A. Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and 124iodine in patients with breast cancer. Int J Cancer 1991; 47: 344–347
   PubMed Web of Science ®Google Scholar
• Miraldi F. Monoclonal antibodies and neuroblastoma. Semin Nucl Med 1989; 19: 282–294
   PubMed Web of Science ®Google Scholar
• Koh W J, Rasey J S, Evans M L, Grierson J R, Lewellen T K, Graham M M, Krohn K A, Griffin T W. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1991; 22: 199–212
   Web of Science ®Google Scholar
• Rasey J S, Koh W, Grierson J R, Grunbaum Z, Krohn K A. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989; 17: 985–992
   PubMed Web of Science ®Google Scholar
• Rasey J S, Nelson N J, Chin L, Evans M L, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 1990; 122: 301–308
   PubMed Web of Science ®Google Scholar
• Tsurumi Y, Kameyama M, Ishiwata K, Katakura R, Monma M, Ido T, Suzuki J. 18F-fluoro-2'deoxyuridine (FUdR) as a tracer of nucleic acid metabolism in brain tumors. J Neurosurg 1990; 72: 110–113
   PubMed Web of Science ®Google Scholar
• Wolf W, Presant C A, Servis K L, EI-Tahtawy A, Albright M J, Barker P B, Ring R, III, Atkinson D, Ong R, King M, Singh M, Ray M, Wiseman C, Blayney D, Shani J. Tumor trapping of 5-fluorouracil: In vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc Natl Acad Sci USA 1990; 87: 492–496
   PubMed Web of Science ®Google Scholar
• Yang D, Emran A, Tansey W, Tilbury R, Rasi L, Wright K, Kuang L, Wallace S, Kim E. Radiosynthesis of fluorotamoxifen analogs. J Nucl Med 1990; 31: 903, (abstract)
   Google Scholar
• Blau M, Ganatra R, Bender M A. F-18 fluoride for bone imaging. Semin Nucl Med 1972; 2: 31–37
   PubMedGoogle Scholar
• Reeve J, Arlot M, Wooton R, Edouard C, Tellez M, Hesp R, Green J R, Meunier P J. Skeletal blood flow, iliac histomorphometry, and strontium kinetics in osteoporosis: A relationship between blood flow and correct apposition rate. J Clin Endocrinol Metab 1988; 66: 1124–1131
   PubMed Web of Science ®Google Scholar
• Charkes N D, Makler P T, Jr., Phillips C. Studies of skeletal tracer kinetics. I. Digital computer solution of a five-compartment model of [18F]fluoride kinetics in humans. J Nucl Med 1978; 19: 1301–1309
   PubMed Web of Science ®Google Scholar
• Hawkins R A, Choi Y, Huang S C, Hoh C K, Dahlbom M, Schiepers, Satyamurthy N, Barrio J, Phelps M E. Evaluation of skeletal kinetics of [18F]fluoride ion with PET. J Nucl Med 1992; 33: 633–642
   PubMed Web of Science ®Google Scholar
• Hawkins R A, Hoh C, Glaspy J, Yong C, Dahlbom M, Rege S, Messa C, Nietszche E, Hoffman E, Seeger L, Maddahi J, Phelps M E. Role of PET in oncology and other whole body applications. Semin Nucl Med 1992; 22: 268–284
   PubMed Web of Science ®Google Scholar
• Guerrero T M, Hoffman E J, Dahlbom M, Hawkins R A, Phelps M E. Characterization of a whole body imaging technique for PET. IEEE Trans Nucl Sci 1990; 37: 676–680
   Web of Science ®Google Scholar
• Dahlbom M, Hoffman E J, Hoh C K, Schiepers C, Rosenqvist G, Hawkins R A, Phelps M E. Evaluation of a positron emission tomography (PET) scanner for whole body imaging. J Nucl Med 1992; 33: 1191–1199
   PubMed Web of Science ®Google Scholar
• Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: A comparison with DNA flow cytometry in head and neck tumors. Cancer 1988; 61: 1776–1781
   PubMed Web of Science ®Google Scholar
• Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18-fluorodeoxyglucose. J Nucl Med 1988; 29: 1521–1525
   PubMed Web of Science ®Google Scholar
• Haberkorn U, Strauss L G, Reisser Ch, Haag D, Dimitrakopoulou A, Ziegler S, Oberdorfer F, Rudat V, Van Kaick G. Glucose uptake, perfusion and cell proliferation in head and neck tumors: Relation of positron emission tomography to flow cytometry. J Nucl Med 1991; 32: 1548–1555
   PubMed Web of Science ®Google Scholar
• Jabour B A, Choi Y, Hoh C K, Rege S D, Soon J C, Lufkin R B, Hanafee W N, Maddahi J, Chaiken L, Bailet J, Phelps M E, Hawkins R A. PET imaging of the extracranial head and neck using 2-[18F]fluoro-2-deoxy-D-glucose (FDG) with MRI correlation. Radiology 1993; 186: 27–35
   PubMed Web of Science ®Google Scholar
• Wahl R L, Kaminski M S, Ethier S P, Hutchins G D. The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 1990; 31: 1831–1835
   PubMed Web of Science ®Google Scholar
• Chaiken L, Rege S, Hoh C, Choi Y, Jabour B, Juillard G, Hawkins R A, Parker R. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys, (in press)
   PubMedGoogle Scholar
• Verbeek A LM, Hendriks J H, Holland R, Mravunac M, Sturmans F, Day N E. Reduction of breast cancer mortality through mass screening with modern mammography. Lancet 1984; 1: 1222–1224
   PubMed Web of Science ®Google Scholar
• Chavaudra N, Richard J M, Malaise E P. Labelling index of human squamous cell carcinomas. Comparison of in vivo and in vitro labelling methods. Cell Tissue Kinet 1979; 12: 145–152
   PubMedGoogle Scholar
• Blijham G, Schutte B, Reynder M, Wiggers Th, Arends J, Volovics L, Bosman F. Flowcytometric (FCM) determination of ploidy level and life cycle analysis on 297 paraffin embedded colorectal carcinoma specimens. Proc Am Soc Clin Oncol 1985; 4: 22
   Google Scholar
• Tubiana M, Pejovic M G, Chavaudra N, Contesso G, Malaise E P. The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer 1984; 33: 441–445
   PubMed Web of Science ®Google Scholar
• Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: Correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 1987; 235: 177–182
   PubMed Web of Science ®Google Scholar
• Slamon D J, Godolphin W, Jones L A, Hold J A, Wong S G, Keith D E, Levin W J, Stuart S G, Udove J, Ullrich A, Press M F. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707–712
   PubMed Web of Science ®Google Scholar
• Slamon D J, Press M F, Godolphin W, Ramos L, Haran P, Shek L, Stuart S G, Ullrich A. Studies of the HER-2/neu protooncogene in human breast cancer. Cancer cells 1989; 7: 371
   Google Scholar
• Slamon D J. Protooncogenes and human cancers. N Engl J Med 1987; 317: 955–957
   PubMed Web of Science ®Google Scholar
• Wahl R L, Cody R L, Hutchins G D, Mudgett E E. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765–770
   PubMed Web of Science ®Google Scholar
• Tse N, Hoh C K, Hawkins R A, Dahlbom M, Maddahi J, Phelps M E, Glaspy J A. Application of positron emission tomography with 2-[F-18]fluoro-2-deoxy-D-glucose (FDG) to the evaluation of breast masses. Ann Surg 1992; 216: 27–34
   PubMed Web of Science ®Google Scholar
• Wahl R L, Cody R, Zasadny, Hutchins G, Helvie M. Active breast cancer chemohormonotherapy sequentially assessed by FDG PET: Early metabolic decrements precede tumor shrinkage. J Nucl Med 1991; 32: 982, (abstract)
   Google Scholar
• Goldenberg D M, Larson S M. Radioimmunodetection in cancer identification. J Nucl Med 1992; 33: 803–814
   PubMed Web of Science ®Google Scholar
• Rege S D, Hoh C K, Glaspy J A, Aberle D R, Dahlbom M, Razavi M K, Phelps M E, Hawkins R A. Imaging of pulmonary mass lesions with whole body positron emission tomography and fluorodeoxyglucose, (submitted)
   Google Scholar
• Nolop K B, Rhodes C G, Brudin L H, Beaney R P, Krauz T, Jones T, Hughes J MB. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60: 2682–2687
   PubMed Web of Science ®Google Scholar
• Kern K A, Brunetti A, Norton J A, Chang A E, Malawer M, Lack E, Finn R D, Rosenberg S A, Larson S M. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988; 29: 181–186
   PubMed Web of Science ®Google Scholar
• Minn H, Soini I. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989; 15: 61–66
   PubMedGoogle Scholar
• Adler L P, Blair H F, Makley J T. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32: 1508–1512
   PubMed Web of Science ®Google Scholar
• Gold R H, Hawkins R A, Katz R D. Imaging osteomyelitis—From plain films to MRI: A pictorial essay. Am J Roentgenol 1991; 157: 365–370
   PubMed Web of Science ®Google Scholar
• Strauss L G, Clorius H J, Schlag P, Lehner B, Kimming B, Engenhart, Marin-Grez M, Helus F, Oberdorfer F, Schmidlin P, Van Kaick G. Recurrence of colorectal tumors: PET evaluation. Radiology 1989; 170: 329–332
   PubMed Web of Science ®Google Scholar
• Paul R. Comparison of fluorine-18–2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987; 28: 288–292
   PubMed Web of Science ®Google Scholar
• Haberkorn U, Strauss L G, Knopp M V, Dimitrakopoulou A, Engenhart R, Oberdorfer F, Ostertag H, Romahn J, van Kaick G. PET studies of FDG metabolism in patient with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991; 32: 1485–1490
   PubMed Web of Science ®Google Scholar
• Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, Hayashi H, Asano T, Ryu M. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: Characterization of tumor and assessment of effect of treatment. J Nucl Med 1992; 33: 33–339
   PubMedGoogle Scholar
• Harney J V, Wahl R L, Liebert M, Kuhl D E, Hutchins G D, Wedemeyer G, Grossman H B. Uptake of 2-deoxy, 2-(18F)fluoro-D-glucose in bladder cancer: Animal localization and initial patient positron emission tomography. J Urol 1991; 145: 279–283
   PubMed Web of Science ®Google Scholar